{"name":"Portola Pharmaceuticals","slug":"portola-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Andexanet","genericName":"Andexanet","slug":"andexanet","indication":"Direct acting anticoagulant adverse reaction","status":"marketed"}]}],"pipeline":[{"name":"Andexanet","genericName":"Andexanet","slug":"andexanet","phase":"marketed","mechanism":"Biologic","indications":["Direct acting anticoagulant adverse reaction"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOUTAybUhZc2xYVmRpS0NkT1BDUFFBR2EtWUc5TG5qY2xxRjFGbERiTzByeEJEb3JoaDU5bFZnN3dndWgzWF9xcFI1UTNzMUFsb1VzSURpTzktdjJTTlg5THlfYXpEbzQ2eGlwTGt0YkV6ZUVISVp1RHdYMHVIOUhEbXNDWk03aVB3MllPMTc5cGFlMjVuNUhnTVhiQ3kzb1NSalRWUkcwMUFSb1dVeURKeUNOOTViQQ?oc=5","date":"2025-12-19","type":"regulatory","source":"Fierce Pharma","summary":"AstraZeneca to pull bleeding reversal agent Andexxa after FDA flags risk imbalance - Fierce Pharma","headline":"AstraZeneca to pull bleeding reversal agent Andexxa after FDA flags risk imbalance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOMnZyci1XT25EN283akc5SUxIdGFqVUJRMVpBbmhnbXZoNXhkNEpybE15eU5lakdHbHppZlBmbHMyZ0dCZ0lrUW01RGF3cURuV1BYTl9TQVpxT1B5SnpIb3ZjM2JnbFg1T2RjdTZUdTFHWF9hd2lLN2pkbllPWmtmQ1M5SjZPQlE0ak0zNFR0U0l5d25oQ3RlLVBWc3pFZVZvSmV0QWhrSGdnMmc3cVQ3aXM5WjFFRkFwX1oycV9uNUY?oc=5","date":"2021-08-11","type":"pipeline","source":"reuters.com","summary":"Portola Pharmaceuticals, underwriters lose bid to toss shareholder lawsuit - reuters.com","headline":"Portola Pharmaceuticals, underwriters lose bid to toss shareholder lawsuit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPVzZSa2NPMEhuRVVMbm0xa2ktbWduaFVRd3paOTVFbXNsTHROc1VDbFFDdnh3ZGRCVFQ3U0ZZZ29ydUZCUlFTZVVZZS1FNy1ocFdzS1hvM2JxVVd5SFRManpQNjJFOTFLVGJQN0dFZC00NnhjVXNuVXhDU29UWU81OA?oc=5","date":"2021-03-05","type":"pipeline","source":"BioSpace","summary":"Former Portola CEO Takes the Helm at T-Cell Cancer Therapy Company - BioSpace","headline":"Former Portola CEO Takes the Helm at T-Cell Cancer Therapy Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPMU1pQUZvTDRDRUFVVG53MXIxTV9kY0pKQ2VGc01LR2VXeF8wcEJoaUhUNnhJSkdPZTZSY1Bwc0U0U0RWX0V2QkJ5X3M0Tml1ZnVNRS1ib2VuWFRibVJvNWpxSDFBQy01aDVsTmVHcmg2Q1VHS18tTWxVNURWR0tzeEtoSXRpaFFrRFlDek5Zem5jTExrUXNQNldOWFJCcFhU?oc=5","date":"2020-05-12","type":"deal","source":"Fierce Pharma","summary":"Activist investor blasts Alexion's $1.4B Portola buy in scathing open letter - Fierce Pharma","headline":"Activist investor blasts Alexion's $1.4B Portola buy in scathing open letter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQZERsMkN0WmlLUU5WdlEtTlB1SUxpVFR6ZmFjcWZrdEpzeXZCM2JLa2psWmdMVnktTjBOMHNHaVRORl9hZGJ5dmt0LUFDYkhKZVpNMk00cC1lbjJ5cml5WVlDLVBZT1hnc0dYZUpnQzZLRURKS1UwSzFLRjFkN3BsSTRjVVJuNjg?oc=5","date":"2020-05-06","type":"deal","source":"Contract Pharma","summary":"Alexion to Acquire Portola for $1.4B - Contract Pharma","headline":"Alexion to Acquire Portola for $1.4B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOUUsya21HS2xNcDN6Q28wU2xxUjZtRVl6SmsxeVpQeGFXSGFJVlJxV2xwNjNPaTVVQzVxTjZaSE14SndFaS00T2sxNi14VUY5eWN0bkJwQlVrYzZyd2lzN1BpUThsOVhwaFRDT0hoYXYyMDNCM0dlWGsxcGY2b09uZW9tUW80aC1tM1VjaGlURQ?oc=5","date":"2020-05-05","type":"deal","source":"BioSpace","summary":"Alexion Set to Acquire Portola Pharmaceuticals in $1.41 Billion Deal - BioSpace","headline":"Alexion Set to Acquire Portola Pharmaceuticals in $1.41 Billion Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNengzelJqandoWFZfRVlYMzd2SEgyZndLdDZZRUV4dDNjd2U1YlBuYklDUWNlWFJKNXZKTWY5WXRaX29MR1Qxb2h3N0RwNS0xTGRocWR4ckd0NjN0dEtMejkwbVJoVGdIdExYZEdzSi0yVzB2WW9zZjkwbVh2YnNlUHRfNTEwLXR0N0ZPSTVB?oc=5","date":"2020-05-05","type":"deal","source":"BioPharma Dive","summary":"Alexion, seeking to broaden business, to buy Portola for $1.4B - BioPharma Dive","headline":"Alexion, seeking to broaden business, to buy Portola for $1.4B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQeUh5cFZYZUx6N1dsaGFuTWttQ2UxdS1lX3VPaV95ZGxvQlNBUnlZZUhKM1lOSlZhOEZVeG5KcTVYc19JSkI3V0JpNVdBTVk4ZmhOc1dJUEhuYWJSSUMzdW5GWXVYbHVNcnU3QjZ1TnlWdUZoYjNpWXdhb0RaeElxTmVScmlKcVVhWjgw?oc=5","date":"2020-05-05","type":"deal","source":"Business Wire","summary":"Alexion to Acquire Portola - Business Wire","headline":"Alexion to Acquire Portola","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPUjlvUG5PSVNWaEpkT1drN0xMbmY5TGRyTlNUNUhva191ZWVTMlVOd2JHMVMxLUxOcU55aFdra0ZOQXFUSkZiNXRhVmF4V1VUdnkzUjUzWE5kTUtGRkRVNkRxTzdheXpZUlRtR0R1b3RKdG1CMkZjYzBkMV9YT203ZEx5QlM5UlhTdHlPZHh0MENHYWZNVERobmFjS19JVmNldFdCaGJiQ3g?oc=5","date":"2020-05-05","type":"pipeline","source":"Fierce Pharma","summary":"Alexion bets $1.4B on Portola and its laggard bleeding drug Andexxa - Fierce Pharma","headline":"Alexion bets $1.4B on Portola and its laggard bleeding drug Andexxa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNYWd2LWtuVmUzNnZPS0t2TjdlakZ5WWU5SmdyTEVoTjU0ZzlUdnZYd2NpRFVSRlFxZThjRzRya2tmS2dJQ2ZsYVhicUFRd0VPUVE2ZEVuMnM1eGFNWUw3dUtVbnRISjh4Vk5jcEJySmRXQjN2a245eUI5UDlzSlNCOHZlUEJBUG9TdXd0OHJaVE45YnJfSi1jU0dJcnJBOHhZTk80?oc=5","date":"2018-09-11","type":"pipeline","source":"BioPharma Dive","summary":"Portola’s C-suite shrinks as chief commercial officer exits - BioPharma Dive","headline":"Portola’s C-suite shrinks as chief commercial officer exits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFA5V1BlaEE5R0FNSVRPUlBhXzNKd0VFODV6UGdyMjlfelY5YU1VTlgtdTZWeDFsbXlQWHY4QVhkOUNjSVE4N0gzd3hQcERPV3h4Sm1IYk1sYWRySnFjblgtRTZaX3AxZjlGdmk1LS10enlzN2xYamVySEx0WQ?oc=5","date":"2018-05-04","type":"regulatory","source":"BioSpace","summary":"FDA Gives Portola Pharma’s Andexxa a Thumbs-up - BioSpace","headline":"FDA Gives Portola Pharma’s Andexxa a Thumbs-up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQQjRNbTVhcGtBcmZRUEQ1QjBtN3NuaS1XanZnNkJPZllHVFItVVBPenhoSC1tbmNva0FTQjRYT3hIandDZWZiNjZIaUwwS0g2eWJWU1lmczNvcktfWWpqY3Izemp5bFlyaVVGbHFVOGNuOThob1RTdGZ3SnRsbDhSclZOdklFMHpYSFVGX2J1b29wUEludk9J?oc=5","date":"2016-11-03","type":"deal","source":"BioPharma Dive","summary":"Portola broadens AndexXa partnership with Daiichi - BioPharma Dive","headline":"Portola broadens AndexXa partnership with Daiichi","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}